Journal of Psychopharmacology最新文献

{"title":"Corrigendum to: Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments.","authors":"","doi":"10.1177/02698811251370963","DOIUrl":"https://doi.org/10.1177/02698811251370963","url":null,"abstract":"","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251370963"},"PeriodicalIF":5.5,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Self-treatment of psychiatric conditions using ketamine: Patterns, characteristics, and retrospective insights.","authors":"Gabrielle Smith, Timothy Piatkowski, Jason Ferris, Benjamin Bonenti, Emma Davies, Monica J Barratt, Celia Morgan, Adam Winstock, Cheneal Puljević","doi":"10.1177/02698811251378509","DOIUrl":"https://doi.org/10.1177/02698811251378509","url":null,"abstract":"<p><strong>Background: </strong>While research on novel therapeutic applications of ketamine is expanding, particularly in controlled settings, there is limited exploration of its consumption related to self-treatment of psychiatric conditions. This study investigated the characteristics of people who use ketamine and psychedelics for self-treatment of psychiatric conditions, providing insight into patterns of use within this population.</p><p><strong>Methods: </strong>Utilising the 2020 Global Drug Survey, the analysis incorporates data from 5831 respondents who reported self-treating with unregulated drugs to treat diagnosed psychiatric conditions. We compare three groups: those self-treating with only ketamine (<i>n</i> = 242), ketamine and other psychedelics (<i>n</i> = 1072), and non-ketamine psychedelic only substances (<i>n</i> = 4517). Negative binomial regression was conducted to assess the impact of self-treating psychiatric conditions with ketamine and other psychedelics on the volume of recreational ketamine use.</p><p><strong>Results: </strong>A high proportion (>60%) had prior psychiatric diagnoses, with depression and anxiety being the most common. People who used both ketamine and other substances reported higher festival and clubbing attendance than the other two groups. People who used ketamine and combined it with other psychedelics used it more frequently (incidence rate ratio (IRR): 0.729, 95% confidence interval (CI): 0.336-1.581), while those using non-ketamine psychedelics only showed a significant reduction in ketamine usage volume (IRR: 0.160, 95% CI: 0.079-0.322) compared to other groups. Almost half of the respondents sought online advice before starting ketamine self-treatment.</p><p><strong>Conclusion: </strong>This study extends knowledge about various populations using ketamine for self-treatment purposes, proposes areas for future research and suggests online platforms as the most effective place for harm reduction resources relating to ketamine use.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251378509"},"PeriodicalIF":5.5,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape analysis of pre-registered clinical trials involving classical psychedelics.","authors":"Abdo Uyar, Linda Forbrich, Ulrike Lueken, Ricarda Evens","doi":"10.1177/02698811251371690","DOIUrl":"https://doi.org/10.1177/02698811251371690","url":null,"abstract":"<p><p>Psychedelic clinical research is expanding rapidly. This review analyses the state and trends in psychedelic clinical trial registrations. A systematic search of ClinicalTrials.Gov was conducted on 11 November 2024, to identify registered interventional trials investigating (therapeutic) effects of serotonergic psychedelics (e.g. lysergic acid diethylamide [LSD], psilocybin, [5-MeO-]DMT). Analyses included a negative binomial regression to assess time trends and descriptive summaries of study characteristics. Outcomes included registration trends, substance distribution, study phase progression, sample and trial characteristics, geographical distribution and psychotherapy reporting. A total of 241 trials were identified, with registrations rising exponentially after 2006 and an acceleration post-2019. Two-thirds of trials are ongoing or planned. Psilocybin remains the most frequently studied substance and is most advanced towards approval, but short-acting psychedelics ([5-MeO-]DMT) have recently been introduced with a more focused clinical scope. Industry involvement is increasing, though university-led research still dominates. Reports of psychotherapy components increased following 2023 FDA recommendations, though no major improvements in intervention descriptions were observed. The rapid expansion of registered psychedelic clinical trials with diverse indications and substances reflects growing clinical interest. While university-led studies initiated early investigations and established a broad knowledge base, later industry involvement increasingly prioritizes scalability and economic considerations by adopting a focused approach towards clinical approval. Inconsistent reporting of psychotherapeutic components limits cross-study comparability and complicates systematic investigations into which combinations of therapeutic elements (type, timing, intensity) may optimize clinical outcomes. Future efforts should focus on complete and standardized trial reporting at study registration to minimize bias, reduce interpretative ambiguity and facilitate cross-trial comparisons.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251371690"},"PeriodicalIF":5.5,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145345872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Community-based causal evidence that high habitual caffeine consumption alters distinct polysomnography-derived sleep variables.","authors":"Benjamin Stucky, Leonard Henckel, Marloes H Maathuis, José Haba-Rubio, Pedro Marques-Vidal, Francesca Siclari, Raphaël Heinzer, Hans-Peter Landolt","doi":"10.1177/02698811251368364","DOIUrl":"https://doi.org/10.1177/02698811251368364","url":null,"abstract":"<p><strong>Background: </strong>Controlled laboratory studies demonstrate that caffeine acutely impairs sleep quality. However, the impact of daily caffeine intake, which is common in society, on community-derived physiological sleep measures is unknown.</p><p><strong>Aims: </strong>Because good quality sleep is important for general health and well-being, we explored causal effects of habitual caffeine consumption on objective and subjective sleep variables collected at home.</p><p><strong>Methods: </strong>We used dedicated, two-sample Mendelian Randomization (MR) and causal matching methods, including MR-Egger, inverse variance weighting, and weighted median, to analyze large community-based datasets taken from the UK Biobank (<i>n</i> = 485,511) and the HypnoLaus (<i>n</i> = 1702) cohorts.</p><p><strong>Results: </strong>While self-rated sleep quality and morningness-eveningness did not differ, all statistical models revealed that four or more caffeinated beverages per day shorten total sleep time when compared to fewer caffeine containing drinks per day. The estimated reductions in sleep length varied from 11 to 229 minutes. Intriguingly, consistent with the homeostatic facet of sleep-wake regulation, the shorter sleep in high habitual caffeine consumers was characterized by increased non-rapid-eye movement sleep depth as measured by all-night electrical brain activity.</p><p><strong>Conclusions: </strong>The data show that high habitual caffeine intake alters the characteristics of sleep in the general population, while sparing the major physiological principles of sleep-wake regulation possibly due to adaptation.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251368364"},"PeriodicalIF":5.5,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of lithium on cognition in humans: A systematic review.","authors":"Talitha Najmillah Sabtiari, Samuel Myrtle, Stelios Orfanos, Allan H Young, Rebecca Strawbridge","doi":"10.1177/02698811251371139","DOIUrl":"https://doi.org/10.1177/02698811251371139","url":null,"abstract":"<p><strong>Background: </strong>Lithium, a mainstay treatment for bipolar disorders, has shown promise in treating cognitive impairments. However, concerns about cognition-related side effects persist.</p><p><strong>Aims: </strong>We aimed to synthesise the evidence on how lithium affects cognition by comparing cognitive performance before and after starting lithium treatment.</p><p><strong>Methods: </strong>A systematic search was conducted to identify studies examining lithium's effects on cognition. The review considered studies with adult human participants that reported quantitative cognitive outcomes using within-subject comparisons between lithium-absent and lithium-present conditions.</p><p><strong>Results: </strong>Thirty-two articles describing 30 studies were included (727 participants, approximately 54% female, mean age ± 50 years old). The studies exhibited significant heterogeneity within cognitive domains, including global cognition (15 studies), memory (19 studies), processing and psychomotor speed (8 studies), attention (9 studies), verbal fluency (4 studies) and executive function (6 studies). The included studies comprised 16 randomised controlled trials (RCTs) and 14 non-RCTs, with study populations ranging from individuals with affective disorders (13 studies) to neurocognitive disorders (11 studies) and healthy individuals (6 studies). Some studies reported cognitive enhancements, particularly in individuals with affective disorders, while others documented declines or mixed results.</p><p><strong>Conclusions: </strong>Definitive conclusions regarding lithium's isolated cognitive effects remain elusive, particularly considering the influence of factors such as affective state, population and methodological heterogeneity among studies. Further research is needed to conclusively determine the raw cognitive impacts of lithium therapy, requiring larger RCTs across distinct populations. Prioritising the resolution of main symptoms should remain the primary therapeutic goal of lithium treatment.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251371139"},"PeriodicalIF":5.5,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145308603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel psychedelic 5-HT_2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.","authors":"Gerard J Marek, Soma Makai-Bölöni, Daniel Umbricht, Edward P Christian, Jason Winters, Dino Dvorak, Shane Raines, Zoë A Hughes, Eric W Austin, Adam K Klein, William Leong, Fas J Krol, Anne J van der Graaf, Maria J Juachon, Marije E Otto, Laura G J M Borghans, Gabriël Jacobs, Andrew C Kruegel, Jonathan Sporn","doi":"10.1177/02698811251378512","DOIUrl":"https://doi.org/10.1177/02698811251378512","url":null,"abstract":"<p><strong>Background: </strong>The treatment of major depressive disorder (MDD) with available antidepressant drugs is characterized by considerable ineffectiveness. Classical psychedelics such as psilocybin and N,N-dimethyltryptamine (DMT), which act primarily as 5-hydroxytryptamine 2A (5-HT_2A) receptor agonists, have shown preliminary efficacy for inducing long-term remission in MDD after one or two doses. GM-2505 is a novel, 5-HT_2A receptor agonist, developed for treating MDD.</p><p><strong>Methods: </strong>In this single-ascending dose, randomized, placebo-controlled, double-blind study, we characterized GM-2505's safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profile in 48 healthy participants.</p><p><strong>Results: </strong>Single intravenous (IV) doses up to 20 mg demonstrated an acceptable safety profile of mild transient adverse events, short-term, non-clinically significant increases in blood pressure and pulse, and no significant changes in electrocardiographs, consistent with other 5-HT_2A receptor agonists. In general, GM-2505 <i>C</i>_max and AUC_last increased dose proportionally, with <i>t</i>_1/2 of 40-50 minutes. Generally, dose-dependent effects were observed for neuroendocrine hormones, several neuropsychological and neurophysiological measures, and subjective drug effects. Dose-related effects were also observed in resting-state electroencephalography (rsEEG), with decreased power in the low frequency rsEEG bands (theta and alpha), and increased in the high frequency bands (slow and fast gamma).</p><p><strong>Conclusions: </strong>These PD findings were similar in nature and magnitude to other 5-HT_2A receptor agonists that have been studied clinically. In line with the GM-2505 PK profile, the duration of cardiovascular and subjective effects was shorter than psilocybin but longer than DMT, demonstrating a potentially more practical temporal profile for use in a supervised clinical setting compared to longer-acting 5-HT_2A receptor agonists, with an optimal dose range of 10-15 mg IV. Clinical trial (ISRCTN64428072) registration: https://www.isrctn.com/ISRCTN64428072.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251378512"},"PeriodicalIF":5.5,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of electroconvulsive shock on astroglial reactivity in a rat model of antipsychotic-induced neurotoxicity.","authors":"Yuki Hirose, Yasunori Oda, Fumiaki Yano, Fumiaki Yamasaki, Yusuke Nakata, Yukihiko Shirayama, Tomihisa Niitsu","doi":"10.1177/02698811251382163","DOIUrl":"https://doi.org/10.1177/02698811251382163","url":null,"abstract":"<p><strong>Objectives: </strong>Electroconvulsive shock (ES) can ameliorate psychotic symptoms and certain adverse effects of antipsychotics by inducing seizure activity via electrical brain stimulation. Although the relationship between ES and glial cells has been the focus of attention, the precise mechanisms underlying its effects remain unclear. This study aimed to investigate the effects of ES on astroglia in the drug-induced neurotoxicity rat model.</p><p><strong>Methods: </strong>Haloperidol (HAL; 0.75 mg/kg/day for 28 days) or vehicle was administered to rats via an osmotic mini-pump, then received repeated seizure-inducing electrical stimulus (80 mA, 100 Hz, for 1 seconds with a pulse width of 0.5 mseconds) or sham operation twice daily for five consecutive days. The levels of glial fibrillary acidic protein (GFAP), glutamate transporter-1, and glutamine synthetase were determined in the brain regions.</p><p><strong>Results: </strong>ES treatment led to GFAP expression, which is indicative of astrocyte activation. In the CA1 region, astrocytic changes associated with neurotoxicity were observed in the HAL-treated group. Furthermore, astroglial reactivity in this region was ameliorated following ES.</p><p><strong>Conclusions: </strong>The present study suggests that ES could activate the astrocytic system. Furthermore, our results also showed that ES may mitigate neurotoxic damage induced by antipsychotics. In view of the need for therapeutic strategies for treatment-resistant psychiatric disorders, further investigations of our findings are warranted.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251382163"},"PeriodicalIF":5.5,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs.","authors":"David J Heal, Jane Gosden, Sharon L Smith","doi":"10.1177/02698811251382147","DOIUrl":"https://doi.org/10.1177/02698811251382147","url":null,"abstract":"<p><p>Psychedelic research is progressing at breakneck speed and is creating new challenges for drug developers, regulatory authorities, and legislators. Most \"classic\" psychedelics undergoing clinical investigation are C-I controlled drugs with perceived high potential for abuse and no medical use. These and next-generation psychedelic drug-candidates require scientific and clinical assessment of their abuse and dependence potential before transitioning into a controlled drug schedule assigned to clinically approved drugs (C-II to C-V). Food and Drug Administration is likely to undertake the first regulatory assessment of a \"classic\" psychedelic, and it has led in disseminating advice on how to address the clinical and regulatory challenges. We have built on this foundation by discussing areas of abuse and dependence evaluation procedures that remain unclear or have not previously been covered. Psychedelic drug-candidates can be classified into three categories, that is, \"classic\" (well-known compounds including psilocybin, <i>N,N</i>-dimethyltryptamine and lysergic acid diethylamide) and \"novel\" psychedelics (e.g., analogues of known psychedelics), and located between them is what we describe as \"grey area\" psychedelics (e.g., non-hallucinogenic 5-HT_2A agonists). In this review, we set out clear proposals for categorizing psychedelic drug-candidates, describe the development pathway and abuse/dependence testing procedures appropriate to each, and, finally, offer our perspective on how these drugs will be evaluated and scheduled under the auspices of the U.S. Controlled Substances Act. Although we used the United States as a test case, the principles and analyses we used and the screening framework for assessing the abuse potential of psychedelic drug-candidates are universally applicable and can be easily adapted to the regulatory requirements and procedures in other countries.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251382147"},"PeriodicalIF":5.5,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145301699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>β</i>-blockers' neuropsychiatric risks: Overlooked evidence?","authors":"Boyi Liu","doi":"10.1177/02698811251383531","DOIUrl":"https://doi.org/10.1177/02698811251383531","url":null,"abstract":"","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251383531"},"PeriodicalIF":5.5,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: <i>β-blockers' neuropsychiatric risks: Overlooked evidence?</i>","authors":"Lujain Ez Eddin, Mohammad Ali Omrani, Niaz Chalabianloo, Flory T Muanda","doi":"10.1177/02698811251383531#sub1-02698811251383531","DOIUrl":"https://doi.org/10.1177/02698811251383531#sub1-02698811251383531","url":null,"abstract":"","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251383531"},"PeriodicalIF":5.5,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}